Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
Hidalgo
Manuel
M
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, USA. mhidalg1@jhmi.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D002986:Clinical Trials as Topic; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D008495:Medical Oncology / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D066246:ErbB Receptors